FDA Approves Semaglutide for Chronic Kidney Disease in Diabetic Patients, Demonstrating a Reduction in Alzheimer's Disease Risk by 41% to 67%

On January 28, Novo Nordisk announced that the U.S. FDA has approved semaglutide for reducing the risk of kidney failure and disease progression in patients with chronic kidney disease (CKD) who also have diabetes. This approval marks semaglutide as the first GLP-1 medication specifically indicated for the treatment of CKD.

The FDA's decision was primarily based on the results of the FLOW phase 3b trial, which investigated the effects of weekly semaglutide injections on major kidney and cardiovascular outcomes in adults with type 2 diabetes and CKD. Compared to a placebo, patients experienced a 24% reduction in the relative risk of worsening kidney disease, kidney failure (end-stage renal disease), and cardiovascular-related death, demonstrating both statistical significance and superiority.

In August of last year, semaglutide was submitted for domestic approval for this new indication, which is expected to target type 2 diabetes patients with concurrent chronic kidney disease.

In addition to diabetes and weight loss indications, major pharmaceutical companies are competing for differentiated indications for GLP-1 drugs. For instance, Eli Lilly's tirzepatide has been approved for treating obstructive sleep apnea, while Novo Nordisk's semaglutide has received approval for cardiovascular indications.

Furthermore, sources from Yicai Global indicate that Novo Nordisk is conducting clinical trials for semaglutide in relation to Alzheimer's disease and non-alcoholic steatohepatitis (NASH), a common liver condition characterized by fat accumulation.

Recent studies have shown a significant correlation between semaglutide use and a reduced risk of Alzheimer's disease diagnosis in patients with type 2 diabetes. Compared to seven other diabetes medications, those using semaglutide had a 41% to 67% lower risk of developing Alzheimer's disease.

This groundbreaking approval not only highlights the expanding therapeutic potential of semaglutide but also underscores the ongoing efforts to address the complex health challenges faced by patients with diabetes and chronic kidney disease.